Shichao Lv

Dr. Shichao Lv


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Pharmacological Research
Verified
Journal Article
Closed access
QJQiujin Jia
Qiujin Jia
LWLirong Wang
Lirong Wang
XZXiaonan Zhang
Xiaonan Zhang
YDYuejia Ding
Yuejia Ding
HLHao Li
Hao Li
JZJunping Zhang
Junping Zhang

16 November 2019 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
QJQiujin Jia
Qiujin Jia
HLHao Li
Hao Li
HZHuan Zhou
Huan Zhou
XZXiaonan Zhang
Xiaonan Zhang
AZAo Zhang
Ao Zhang
JZJunping Zhang
Junping Zhang
Although the mechanism of the occurrence and development of heart failure has been continuously explored in the past ten years, the mortality and readmission rate of heart failure is still very high. Modern studies have shown that gut microbiota is associated with a variety of cardiovascular diseases, among which the study of gut microbiota and heart failure attracts particular attention. Therefore, understanding the role of gut microbiota in the occurrence and development of heart failure will help us further understand the pathogenesis of heart failure and provide new ideas for its treatment. This paper introduced intestinal flora and its metabolites, summarized the changes of intestinal flora in patients with heart failure, clarified that intestinal barrier damage and bacterial translocation induced inflammation and immune response aggravated heart failure, and altered intestinal microflora affected various metabolic pathways including trimethylamine/TMAO, SCFA, and Bile acid pathway leads to heart failure. At the same time, regulating intestinal microflora through diet, probiotics, antibiotics, fecal transplantation and microbial enzyme inhibitors has grown up to be a potential treatment for many metabolic disorders.

2 August 2019 in Bioscience Reports
Verified
Journal Article
Open access
XZXiaonan Zhang
Xiaonan Zhang
SDShaoyang Dong
Shaoyang Dong
QJQiujin Jia
Qiujin Jia
AZAo Zhang
Ao Zhang
YLYanyang Li
Yanyang Li
JZJunping Zhang
Junping Zhang
Ventricular remodeling (VR) is a complex pathological process of cardiomyocyte apoptosis, cardiac hypertrophy, and myocardial fibrosis, which is often caused by various cardiovascular diseases (CVDs) such as hypertension, acute myocardial infarction, heart failure (HF), etc. It is also an independent risk factor for a variety of CVDs, which will eventually to damage the heart function, promote cardiovascular events, and lead to an increase in mortality. MicroRNAs (miRNAs) can participate in a variety of CVDs through post-transcriptional regulation of target gene proteins. Among them, microRNA-30 (miR-30) is one of the most abundant miRNAs in the heart. In recent years, the study found that the miR-30 family can participate in VR through a variety of mechanisms, including autophagy, apoptosis, oxidative stress, and inflammation. VR is commonly found in ischemic heart disease (IHD), hypertensive heart disease (HHD), diabetic cardiomyopathy (DCM), antineoplastic drug cardiotoxicity (CTX), and other CVDs. Therefore, we will review the relevant mechanisms of the miR-30 in VR induced by various diseases.

1 January 2020 in Aging and disease
Verified
Journal Article
Open access
PDF file
YDYuejia Ding
Yuejia Ding
YWYuan Wang
Yuan Wang
WZWanqin Zhang
Wanqin Zhang
QJQiujin Jia
Qiujin Jia
XWXiaoling Wang
Xiaoling Wang
JZJunping Zhang
Junping Zhang
Myocardial fibrosis is observed in various cardiovascular diseases and plays a key role in the impairment of cardiac function. Endomyocardial biopsy, as the gold standard for the diagnosis of myocardial fibrosis, has limitations in terms of clinical application. Therefore, biomarkers have been recommended for noninvasive assessment of myocardial fibrosis. This review discusses the role of biomarkers in myocardial fibrosis from the perspective of collagen.

11 March 2021 in Journal of Cardiovascular Translational Research
Verified
Journal Article
Closed access
PDF file
WZWan-Qin Zhang
Wan-Qin Zhang
YWYun-Jiao Wang
Yun-Jiao Wang
AZAo Zhang
Ao Zhang
YDYue-Jia Ding
Yue-Jia Ding
XZXiao-Nan Zhang
Xiao-Nan Zhang
JZJun-Ping Zhang
Jun-Ping Zhang

27 January 2019 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
QJQiujin Jia
Qiujin Jia
YXYingyu Xie
Yingyu Xie
CLChunmiao Lu
Chunmiao Lu
AZAo Zhang
Ao Zhang
YLYanmin Lu
Yanmin Lu
JZJunping Zhang
Junping Zhang
Gut microbiota (GM) is a collection of bacteria, fungi, archaea, viruses and protozoa, etc. They inhabit human intestines and play an essential role in human health and disease. Close information exchange between the intestinal microbes and the host performs a vital role in digestion, immune defence, nervous system regulation, especially metabolism, maintaining a delicate balance between itself and the human host. Studies have shown that the composition of GM and its metabolites are firmly related to the occurrence of various diseases. More and more researchers have demonstrated that the intestinal microbiota is a virtual ‘organ’ with endocrine function and the bioactive metabolites produced by it can affect the physiological role of the host. With deepening researches in recent years, clinical data indicated that the GM has a significant effect on the occurrence and development of cardiovascular diseases (CVD). This article systematically elaborated the relationship between metabolites of GM and its effects, the relationship between intestinal dysbacteriosis and cardiovascular risk factors, coronary heart disease, myocardial infarction, heart failure and hypertension and the possible pathogenic mechanisms. Regulating the GM is supposed to be a potential new therapeutic target for CVD.